Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles

Losa, C; Calvo, Pilar; Castro, E Alvarez; Vila-Jato, J. L.; Alonso, Marı́a José

doi:10.1111/j.2042-7158.1991.tb03534.x

Cited by 100 publications

(30 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ever since reports documenting the utility of polycyanoacrylate and poly--caprolactone nanocapsules for ocular administration were published over two decades ago, several publications have highlighted the benefits of using nanosized dosage forms for medical and imaging purposes [1][2][3]. Indeed, advantages such as improved drug solubility and stability, enhanced performance as well as increased efficacy have been well established with nanoparticulate preparations [4].…”

Section: Introductionmentioning

confidence: 99%

A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms

D’Souza

2014

Advances in Pharmaceutics

218

169

View full text Add to dashboard Cite

This review summarizes the methods used to study real-time (37 ∘ C) drug release from nanoparticulate drug delivery systems and establish an IVIVC. Since no compendial standards exist, drug release is currently assessed using a variety of methods including sample and separate (SS), continuous flow (CF), dialysis membrane (DM) methods, and a combination thereof, as well as novel techniques like voltametry and turbidimetry. This review describes the principle of each method along with their advantages and disadvantages, including challenges with set-up and sampling. The SS method allows direct measurement of drug release with simple set-up requirements, but sampling is cumbersome. With the CF method, sampling is straightforward but the set-up is time consuming. Set-up as well as sampling is easier with the DM, but it may not be suitable for drugs that bind to the membrane. Novel methods offer the possibility of real-time drug release measurement but may be restricted to certain types of drugs. Of these methods, Level A IVIVCs have been obtained with dialysis, alone or in combination with the sample and separate technique. Future efforts should focus on developing mathematical models that describe drug release mechanisms as well as facilitate formulation development of nano-sized dosage forms.

show abstract

Section: Introductionmentioning

confidence: 99%

A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms

D’Souza

2014

Advances in Pharmaceutics

218

169

View full text Add to dashboard Cite

show abstract

“…Among the different strategies explored so far, the use of colloidal polymer systems has shown a certain degree of success (2). Previous work by our group and others has indicated that poly(alkylcyanoacrylate) (PACA) nanoparticles (3,4) and poly--caprolactone nanocapsules (5-7) were able to increase the intraocular penetration of drugs, while reducing their systemic absorption. This improved ocular penetration was partially attributed to the interaction and further transport of these colloidal carriers across the corneal epithelium (8).…”

Section: Introductionmentioning

confidence: 99%

Chitosan Nanoparticles as New Ocular Drug Delivery Systems: In Vitro Stability, in Vivo Fate, and Cellular Toxicity

Campos¹,

Diebold²,

Carbalho³

et al. 2005

Pharm Res

View full text Add to dashboard Cite

Purpose. To assess the potential of chitosan (CS) nanoparticles for ocular drug delivery by investigating their interaction with the ocular mucosa in vivo and also their toxicity in conjunctival cell cultures. Methods. Fluorescent (CS-fl) nanoparticles were prepared by ionotropic gelation. The stability of the particles in the presence of lysozyme was investigated by determining the size and their interaction with mucin, by measuring the viscosity of the mucin dispersion. The in vivo interaction of CS-fl nanoparticles with the rabbit cornea and conjunctiva was analyzed by spectrofluorimetry and confocal microscopy. Their potential toxicity was assessed in a human conjunctival cell line by determining cell survival and viability. Results. CS-fl nanoparticles were stable upon incubation with lysozyme and did not affect the viscosity of a mucin dispersion. In vivo studies showed that the amounts of CS-fl in cornea and conjunctiva were significantly higher for CS-fl nanoparticles than for a control CS-fl solution, these amounts being fairly constant for up to 24 h. Confocal studies suggest that nanoparticles penetrate into the corneal and conjunctival epithelia. Cell survival at 24 h after incubation with CS nanoparticles was high and the viability of the recovered cells was near 100%. Conclusions. CS nanoparticles are promising vehicles for ocular drug delivery.

show abstract

“…Ocular bioavailability can be enhanced by increasing corneal drug penetration and prolonging precorneal drug residence time (de Campos et al, 2004). Various drug delivery systems that have been reported till date for increasing ocular bioavailability include ocular inserts (Ding, 1998), collagen shields (Hill et al, 1993), colloidal systems such as liposomes (Pleyer et al, 1993;Bochot et al, 1998), nanoparticles, nanosuspension (Losa et al, 1991;Ding, 1998) and nanocapsules (Losa et al, 1993;de Campos et al, 2003). The literature survey suggests that an appropriate particle size and a narrow size distribution in case of ocular formulation ensure less irritation, adequate bioavailability and compatibility with ocular tissues (Guinedi et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Engineering of polymer–surfactant nanoparticles of doxycycline hydrochloride for ocular drug delivery

Pokharkar¹,

Patil²,

Mandpe³

2014

Drug Delivery

View full text Add to dashboard Cite

Context: Physiologic barriers of the eye, short precorneal drug residence time and poor corneal penetration are the few reasons for reduced ocular bioavailability. Objective: This study was aimed to develop novel polymer-surfactant nanoparticles of hydrophilic drug doxycycline hydrochloride (DXY) to improve precorneal residence time and drug penetration. Materials and methods: Nanoparticles were formulated using emulsion cross-linking method and the formulation was optimized using factorial design. The prepared formulation was characterized for particle size, potential, encapsulation efficiency, in vitro drug release and ex vivo drug diffusion studies. The antibacterial activity studies were also carried out against Escherichia coli and Staphylococcus aureus using the cup-plate method. In vivo eye irritation study was carried out by a modified Draize test in rabbits. Results and discussion: The particle size was found to be in the range of 331-850 nm. About 45-80% of the drug was found to be encapsulated in the nanoparticles. In vitro release demonstrated sustained release profile. Lower flux values in case of nanoparticles as compared to DXY pure drug solution in ex vivo diffusion studies confirmed the sustained release. The nanoparticles were found to be significantly effective (p50.001) than DXY aqueous solution due to sustained release of doxycycline from nanoparticles in both the E. coli and S. aureus strains. The formulation was found to be stable over entire stability period. Conclusion: The developed formulation is safe and suitable for sustained ocular drug delivery.

show abstract

Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles

Cited by 100 publications

References 16 publications

A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms

A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms

Chitosan Nanoparticles as New Ocular Drug Delivery Systems: In Vitro Stability, in Vivo Fate, and Cellular Toxicity

Engineering of polymer–surfactant nanoparticles of doxycycline hydrochloride for ocular drug delivery

Contact Info

Product

Resources

About